- Home
- USAU vs CUE Comparison
USAU vs CUE Comparison
Compare USAU & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | CUE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.2M | 233.5M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | USAU | CUE |
|---|---|---|
| Price | $14.93 | $31.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $22.83 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 160.8K | 149.3K |
| Earning Date | 03-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.11 | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | $17,402,000.00 | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $12.23 | $0.17 |
| 52 Week High | $23.72 | $45.50 |
Technical Indicators
Market Signals| Indicator | USAU | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 55.68 |
| Support Level | $14.84 | $24.35 |
| Resistance Level | $16.47 | $32.50 |
| Average True Range (ATR) | 0.61 | 3.03 |
| MACD | -0.15 | 0.40 |
| Stochastic Oscillator | 20.38 | 81.89 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.